Luye Pharma and DCH Auriga Establish an Exclusive Distribution Partnership and Jointly Launch the “We Care About Mental Health” Initiative
Luye Pharma has granted DCH Auriga Singapore exclusive distribution and marketing rights for Seroquel® and Seroquel XR® in Singapore. The two companies pledge to make joint effort to raise awareness of mental health issues as part of the "We Care About Mental Health" initiative. SINGAPORE, Dec. 13, 2022 /PRNewswire/ -- Luye Pharma Group, an international pharmaceutical company...
Epidemic: Modified approach ensures maximum benefit
BEIJING, Dec. 13, 2022 /PRNewswire/ -- A report from chinadaily.com.cn: After three years of battling COVID-19, experts said China is seeing the light at the end of the tunnel as it continues to optimize measures against the epidemic. LI MIN / China Daily On Wednesday, the National Health Commission unveiled 10 changes to the country's COVID-19...
Youth at Risk of Being Left Behind in Asia Pacific Tuberculosis Response, Regional Forum Spotlights
Johnson & Johnson, together with the Global Fund and Asian Venture Philanthropy Network, convene 2nd annual Asia Pacific Tuberculosis Forum to advance progress toward ending tuberculosis in the region Youth are at risk of being missed from diagnosis if not engaged and empowered in fight against TB among key focus at Forum...
CSL Announces Next CEO & Managing Director
Dr Paul McKenzie appointed Chief Executive Officer and Managing Director of CSL from 6 March 2023 MELBOURNE, Australia, Dec. 13, 2022 /PRNewswire/ -- The Board of Directors of CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that it has appointed Dr Paul McKenzie as Chief Executive Officer (CEO) and Managing Director of CSL from...
Versius adopted for gynaecological and urogynaecological procedures at Frances Perry House
Versius has been introduced at Frances Perry House, a private women's hospital in Melbourne to offer patients access to the benefits of robotic surgery for complex cases including hysterectomies CAMBRIDGE, England, Dec. 13, 2022 /PRNewswire/ -- CMR Surgical – the global surgical robotics business – has announced the installation of...
Patients and Doctors Agree on Treatment Goals Only Half the Time, According to JNCCN Study on People with Neuroendocrine Tumors
Researchers from City of Hope find only 30% of people with neuroendocrine tumors consider living longer to be their single top priority; 70% said addressing and overcoming pain, fatigue, or lack-of-function was more important than just prolonging life. JNCCN announces five new Associate Editors from Duke Cancer Institute, City of Hope, Mayo...
Ascletis Announces Positive Phase I Clinical Results of Oral RdRp Inhibitor ASC10 for COVID-19
--The exposure of active drug ASC10-A after twice daily dosing 800 mg double prodrug ASC10 in Chinese subjects was 94% of that after twice daily dosing 800 mg single prodrug molnupiravir in Japanese subjects --Based on Ascletis' Phase I results of ASC10 and molnupiravir's clinical efficacy data in American, Japanese and Chinese patients, 800 mg twice daily of...
Frost & Sullivan Recognizes VitalConnect with the 2022 New Product Innovation Award for Its Leading-edge Wearable Patient Monitoring Device
VitalConnect delivers a cost-effective, 24/7 remote patient monitoring platform that outperforms existing patient monitoring devices on the market. SAN ANTONIO, Texas, Dec. 12, 2022 /PRNewswire/ -- Based on its recent analysis of the wearable biosensor industry, Frost & Sullivan recognizes VitalConnect with the 2022 North America New Product Innovation Award for delivering a world-class biosensor that comfortably monitors patients and detects...
CARsgen Presents Data from China Pivotal Phase II Trial of BCMA CAR T Zevor-cel (CT053) at 2022 ASH Annual Meeting
SHANGHAI, Dec. 12, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that at the 2022 American Society of Hematology (the "ASH") Annual Meeting, the Company presented a poster with the results of...
FDA clears RF Medical’s MYGEN™ M-3004 and MYOBLATE™ Radiofrequency Ablation System
SEOUL, South Korea, Dec. 12, 2022 /PRNewswire/ -- RF Medical Co., Ltd. is a premier Korean-based medical company serving the healthcare industry for almost two decades. Recently, FDA cleared RF Medical's patented MYGEN™ M-3004 generator and MYOBLATE™ radiofrequency ablation system. FDA clears RF Medical’s MYGEN™ M-3004 and MYOBLATE™ Radiofrequency Ablation System. Radiofrequency ablation is evolving at...
